Today we’re celebrating the initiation of Cellarity’s first clinical trial, evaluating CLY-124, a novel, oral globin-switching therapeutic for sickle cell disease. More details in today’s announcement: https://lnkd.in/eDgJrGbk
Cellarity
Biotechnology Research
Somerville, MA 15,627 followers
Rewriting the rules of drug creation
About us
Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.
- Website
-
http://www.cellarity.com
External link for Cellarity
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Somerville, MA
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Drug Discovery, Drug Development, Single Cell Technologies, AI, Artificial Intelligence, and Machine Learning
Locations
-
Primary
Get directions
101 South Street 6th Floor
Somerville, MA 02143, US
Employees at Cellarity
Updates
-
Through single-cell transcriptomics mapping and AI modeling, Cellarity’s drug discovery platform uniquely revealed an undiscovered target controlling the Globin-Switching mechanism. This novel biological insight forms the basis of our clinical program in sickle cell disease, CLY-124. For more: https://lnkd.in/eDgJrGbk
What is globin switching? In people with sickle cell disease, increasing fetal hemoglobin (HbF) can prevent red blood cells from sickling and blocking blood vessels. Reactivating HbF is a recognized therapeutic strategy that can significantly reduce disease burden. Globin switching refers to a novel therapeutic approach that changes the type of hemoglobin a red blood cell produces—switching from adult sickled hemoglobin to fetal hemoglobin. #FlagshipFounded Cellarity recently announced the initiation of its first clinical trial. CLY-124 is a first-in-class, globin-switching oral medicine designed to treat sickle cell disease: https://lnkd.in/eDgJrGbk Flip through more Flagship flashcards to learn more on how Flagship and our companies are pioneering new science to build a better future for people and the planet: https://bit.ly/3FI16LQ
-
-
🌳��Rooted in Science, Growing in Community 🌳 Last week, members of the Cellarity Research team rolled up their sleeves to support local environmental restoration efforts alongside the Mystic River Watershed Association. At Lincoln Park in Somerville, our volunteers worked with forestry experts to plant young bare-root trees—contributing to a stronger tree canopy, improved air quality, and greater biodiversity for the community. We also teamed up with Everett city arborists at Gateway Park, helping restore critical wetland habitat by planting hundreds of saplings with nutrient-rich mulch. These efforts will benefit local birds, pollinators, and the people who call this area home. A big thank you to the Mystic River Watershed Association for leading these impactful initiatives—and for the incredible work you continue to do for both people and planet. 🌎 #CommunityImpact #EnvironmentalStewardship #CellarityInAction #LifeAtCellarity #BiotechForGood
-
-
Cellarity is pleased to welcome Ted Myles as Chief Executive Officer. For more: https://lnkd.in/eHUBZ-cm
-
-
New Research from Cellarity: Smarter Molecular Design with Latent Reinforcement Learning is now published in Nature Scientific Reports! We're excited to share our latest work introducing a novel approach to molecular optimization using Proximal Policy Optimization (PPO) in the latent space of deep generative models — a powerful alternative to discrete molecular edits. Read the paper here: https://lnkd.in/gGcwqrDY Ragy Haddad, Eleni Litsa, Zhen Liu, Daniel Burkhardt, Govinda Bhisetti, Xin Yu. We also had the opportunity to showcase this work as part of NVIDIA MolMIM through the BioNemo Framework — highlighting its potential in real-world drug discovery pipelines. #DrugDiscovery #MachineLearning #ReinforcementLearning #LatentRL #GenerativeModels #PPO #MolecularDesign #MolMIM #NVIDIA #Cellarity
-
We're thrilled that Parul Bordia Doshi, Chief Data Officer at Cellarity, will join Mickey Atwal, Ariella Sasson and Devika G. next week on a panel - Revolutionizing Drug Discovery on Multimodal Data: Opportunities & Challenges!
-
-
At Cellarity, we are harnessing generative chemistry to streamline lead optimization. We are excited to announce our latest pre-print, co-published with NVIDIA, which leverages their BioNemo Framework. In this work, we introduce MOLRL (Molecular Optimization with Latent Reinforcement Learning), our cutting-edge approach that employs reinforcement learning to design and optimize molecules tailored to specific properties. Stay tuned for the code soon. Link to paper: https://lnkd.in/eEXTahGm Contributors: Ragy Haddad, Eleni Litsa, Zhen Liu, Xin Yu, Daniel Burkhardt, Govinda Bhisetti Acknowledgements: Parul Bordia Doshi, Steve Gately, Vega Shah, PhD Danny Reidenbach
Advancing AI-Driven Molecular Design with NVIDIA BioNeMo A recent preprint from Cellarity and NVIDIA explores how the open-source BioNeMo framework enhances AI-driven molecular discovery. The study, Targeted Molecular Generation with Latent Reinforcement Learning, demonstrates how reinforcement learning (RL) in a latent space can improve molecular generation, accelerating advancements in drug discovery and materials design. Key Highlights: ✅ Built with NVIDIA BioNeMo, a generative AI framework tailored for drug discovery. ✅ Leverages latent-space RL to optimize molecular properties more efficiently. ✅ Opens new possibilities for AI-driven molecular design, with applications in pharma and materials science. Check out the full paper ➡️ https://nvda.ws/4hKdVFS #drugdiscovery #NVIDIAhealthcare
-
-
Cellarity is pleased to welcome Alec Reynolds as interim President, bringing more than 17 years of drug development, strategy, operations, and partnering expertise at Celgene and Flagship Pioneering Medicines, where he is COO, to the company as we advance towards the clinic, scale our pipeline, and identify novel biology for additional complex diseases. We thank Fabrice Chouraqui for his leadership, as he moves back to Europe after many years in the U.S. Learn about Cellarity’s leadership team: https://lnkd.in/ex2byjX5 John Leaman Parul Bordia Doshi Erik Spek Cameron Trenor, MD Kat G. Atli Thorarensen Anna O'Driscoll
-
Our Chief Medical Officer Cameron Trenor, MD spoke with PharmaVoice to discuss challenges facing sickle cell disease treatments and how Cellarity is approaching a new treatment option. As the market evolves, we’re seeing changes to address patient safety and treatment costs. While researchers pursue new treatments for sickle cell disease, it’s important to keep patient needs and accessibility at the center of this work. 🔗Learn more: https://bit.ly/3YZS3PY #BiggerLeaps
-
In October, we welcomed a slew of industry peers for medSCAI 2024! Speakers and guests shared insights, collaborated, and explored the future of artificial intelligence and machine learning to foster advancements across industry and academia. From the keynote address to speaker sessions and panel discussions, experts led important conversations about anticipating and tackling head-on the challenges facing AI in drug development. We look forward to continuing the conversations sparked at this year’s event. A big thank you to Aviv Regev, Ryan Cross, Jen Nwankwo, Ph.D., Rory Kelleher, Peter Clark, PhD, Birgit Schoeberl, Cameron Trenor, MD, Mark Murcko, Cole Trapnell, Joey Azofeifa, Paul Blainey and everyone who contributed to making this event unforgettable. For the latest news visit https://lnkd.in/eiAFi8V8